Unlike many therapeutic peptides, Dihexa can cross the blood-brain barrier and promote BDNF signaling , a key process for: These effects have made Dihexa of great interest in treating neurological diseases, age-related cognitive decline, and more recently, brain fog and fatigue
Here, we examine the otoprotective effects of Dihexa in a zebrafish model of chemical ototoxicity
CJC-1295 with DAC (drug-affinity complex) includes a modification that binds the peptide to serum albumin, extending its half-life to roughly 5.8 to 8.1 days
The goal is finding the highest-efficacy timing you can maintain long-term
These medications deliver results that were previously difficult to achieve without surgery, driving intense patient and physician interest
it is not approved for human or veterinary use, and nothing below describes or recommends any form of administration to people